About the Authors

Michael Delves

Affiliation Department of Life Sciences, Imperial College London, London, United Kingdom

David Plouffe

Affiliation Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America

Christian Scheurer

Affiliations Swiss Tropical & Public Health Institute Swiss TPH, Basel, Basel, Switzerland, University of Basel, Basel, Switzerland

Stephan Meister

Affiliation The Scripps Research Institute, La Jolla, California, United States of America

Sergio Wittlin

Affiliations Swiss Tropical & Public Health Institute Swiss TPH, Basel, Basel, Switzerland, University of Basel, Basel, Switzerland

Elizabeth A. Winzeler

Affiliations Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America, The Scripps Research Institute, La Jolla, California, United States of America

Robert E. Sinden

Affiliation Department of Life Sciences, Imperial College London, London, United Kingdom

Didier Leroy

leroyd@mmv.org

Affiliation Medicines for Malaria Venture, Geneva, Switzerland

Competing Interests

EW owns Novartis stock and receives compensation from Novartis. Some of the compounds which are contained in products sold by Novartis to treat malaria (e.g., coartem) are profiled herein. DL is employed by MMV but has no influence at all on the decision for funding a project. Indeed, such a decision is taken based on the recommendations of an independent External Scientific Advisory Committee. All other authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: MD RES SW EAW. Performed the experiments: MD DP SM CS. Analyzed the data: MD CS RES SW DP EAW DL. Wrote the first draft of the manuscript: DL. Contributed to the writing of the manuscript: RES DL. ICMJE criteria for authorship read and met: MD DP CS SM SW EAW RES DL. Agree with manuscript results and conclusions: MD DP CS SM SW EAW RES DL.